Valneva SE (VALN) Receivables - Net (2020 - 2026)
Valneva SE (VALN) posted Receivables - Net of $11.9 million for Q1 2026, down 63.36% sequentially from $32.4 million in Q4 2025, and down 66.36% YoY from $35.3 million in Q1 2025.
Valneva SE (VALN) Receivables - Net (2020 - 2026) Analysis & Trends
Valneva SE has reported Receivables - Net for 7 years, with the latest figure at $11.9 million in Q1 2026.
- Quarterly Receivables - Net fell 66.36% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 66.36% YoY) and the FY2025 annual result came in at $32.4 million, down 15.03% from the prior year.
- Receivables - Net fell to $11.9 million in Q1 2026 per VALN's latest filing, from $32.4 million in the prior quarter.
- Over five years, Receivables - Net peaked at $58.2 million in Q3 2022 and troughed at $11.9 million in Q1 2026.
- A 5-year average of $32.4 million and a median of $32.4 million in 2025 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2023 and 2026: Receivables - Net jumped 112.19% in 2023, then slumped 66.36% in 2026.
- Over 5 years, Receivables - Net stood at $24.5 million in 2022, then surged by 83.02% to $44.8 million in 2023, then slipped by 16.04% to $37.6 million in 2024, then fell by 13.94% to $32.4 million in 2025, then sank by 63.36% to $11.9 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $11.9 million, $32.4 million, and $23.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.99 Mn |
| Jun 30, 2026 | 18.99 Mn |
| Mar 31, 2026 | 11.86 Mn |
| Mar 31, 2026 | 11.86 Mn |
| Dec 31, 2025 | 32.38 Mn |
| Dec 31, 2025 | 32.38 Mn |
| Sep 30, 2025 | 23.47 Mn |
| Sep 30, 2025 | 23.47 Mn |
| Jun 30, 2025 | 27.31 Mn |
| Jun 30, 2025 | 27.31 Mn |
| Mar 31, 2025 | 35.26 Mn |
| Mar 31, 2025 | 35.26 Mn |
| Dec 31, 2024 | 37.62 Mn |
| Dec 31, 2024 | 37.62 Mn |
| Sep 30, 2024 | 33.34 Mn |
| Sep 30, 2024 | 33.34 Mn |
| Jun 30, 2024 | 32.94 Mn |
| Jun 30, 2024 | 32.94 Mn |
| Mar 31, 2024 | 29.64 Mn |
| Mar 31, 2024 | 29.64 Mn |